Compare WRLD & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WRLD | ANNX |
|---|---|---|
| Founded | 1962 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 828.1M | 812.7M |
| IPO Year | 1994 | 2020 |
| Metric | WRLD | ANNX |
|---|---|---|
| Price | $201.84 | $5.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 107.0K | ★ 3.0M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.88 | N/A |
| Revenue | ★ $585,166,700.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.51 | $16,320.74 |
| P/E Ratio | $28.31 | ★ N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $110.00 | $1.85 |
| 52 Week High | $195.07 | $7.18 |
| Indicator | WRLD | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 82.95 | 48.19 |
| Support Level | $165.03 | $4.75 |
| Resistance Level | N/A | $5.79 |
| Average True Range (ATR) | 7.56 | 0.37 |
| MACD | 2.12 | 0.05 |
| Stochastic Oscillator | 97.80 | 54.82 |
World Acceptance Corp operates a small-loan consumer finance (installment loan) business. It offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. The Company generally serves individuals with limited access to other sources of consumer credit such as banks, credit unions, other consumer finance businesses and credit card lenders. The Company also offers income tax return preparation services to its loan customers and other individuals. The traditional installment loan industry is a fragmented segment of the consumer lending industry. The Company has one reportable segment: the consumer finance segment.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.